JCO precision oncologyHumansMaleCarcinomaNeuroendocrineFemale
Actionable Genomic Alterations in Large Cell Neuroendocrine Carcinoma: A European Case Series of Patients Treated With a Small Molecule Inhibitor.
Frank W J Heijboer, Marta Brambilla, Mario Occhipinti, Daniele Lorenzini, Wieneke A Buikhuisen, Liudmila L Kodach, Petros Christopoulos, Albrecht Stenzinger, Lisa M Hillen, Pilar Garrido, Yolanda Lage, Amparo Benito, Colin R Lindsay, Mathew Carter, Judith Herder
Published: 202510.1200/PO-25-00293
Abstract
PURPOSE: Actionable genomic alterations (AGA) are rare in large cell neuroendocrine carcinoma (LCNEC), and outcomes with small molecule inhibitors (SMI) are not well studied. We evaluated SMI response in LCNEC with AGAs, and also assessed molecular t…
Preview only. Read the full abstract at the source